Showing posts with label brain cancer. Show all posts
Showing posts with label brain cancer. Show all posts

Thursday, May 16, 2013

Theralase Advanced Cancer Therapy Research Recognized at Major International Conference


Toronto, Ontario – May 16, 2013, Theralase Technologies Inc. (TSXV: TLT) (“Theralase”) announced today that its researchers have discovered a significant new mechanism of action for a new class of Photo Dynamic Compounds (PDCs), that have been custom designed to destroy cancer cells when activated by a proprietary light source.

The preclinical study, conducted by Theralase scientists and their colleagues at University Health Network’s Princess Margaret Cancer Centre, was presented on May 15, at the Laser World of Photonics conference held in Munich, Germany.

In previous preclinical studies, Theralase’s PDCs have been proven to be promising anti-cancer agents in various cancer models. Their efficacy involved a number of critical cellular processes, including DNA damage and programmed cell death. All PDCs were thought to work primarily by oxygen-dependent mechanisms, ultimately causing cell death in the presence of highly reactive oxygen. In this study; however, scientists established that a new class of Theralase PDCs have an additional “oxygen independent” mechanism of action, which would increase efficacy in the destruction of more clinically aggressive tumours.

The research lead by Dr. Lothar Lilge, Senior Scientist, Ontario Cancer Institute, Princess Margaret Cancer Centre and Dr. Arkady Mandel, Chief Scientific Officer, Theralase has shown that specific metal-based PDCs when tested for effectiveness of cancer destruction in a low oxygen environment were proven to be highly effective in the destruction of human brain cancer cells in-vitro, thus activating this newly discovered pathway. Additionally using this pathway, Theralase scientists confirmed in a preclinical model a complete response rate and the destruction of subcutaneous (under the skin) colon cancer tumours in mice, which were treated with Theralase’s anti-cancer PDC technology. On follow-up, the initial complete response was maintained in two-thirds of the animals for over 1 year without recurrence.

Roger Dumoulin-White, President and CEO of Theralase Technologies Inc. stated, “Recognition of our world class anti-cancer research at the Munich conference is another testament to the cutting edge research our scientists are conducting in this field. Our findings would strongly suggest that Theralase’s PDCs oxygen independent potency would significantly enhance our ability to destroy cancer cells. Tumours in a low oxygen environment have been extremely challenging because this lack of oxygen renders solid tumours much more resistant to therapeutic interventions. Many traditional therapeutic agents, conducted on poorly oxygenated solid core tumours, including any currently FDA approved PDCs, are susceptible to a “self-limiting” activity; whereby, below a critical threshold oxygenation level, their efficacy is progressively reduced resulting in minimal to no cancer cell destruction. This new class of Theralase PDCs are not susceptible to this “self-limiting” activity and as a result maintain their efficacy even in extremely low oxygenated cancerous tumours, such as breast and prostate cancer. As a result, Theralase is extremely excited about the latest research and what it means in the field of cancer destruction. Theralase is committed to the early commercialization of its patented light activated Photo Dynamic Compounds in the areas of anti-cancer and anti-bacterial applications to generate substantial revenues for the Company and hence dramatically increase shareholder value.”

About Theralase Technologies Inc.

Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions Theralase is currently developing patented Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary laser technology.

For further information please visit www.theralase.com , regulatory filings may be viewed by visiting www.sedar.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information, please contact:

Roger Dumoulin-White,                                                                      
President & CEO                                                                                  
416-699-LASE (5273) ext. 225                                                              

Kristina Hachey
Chief Financial Officer
416-699-LASE (5273) ext. 224
khachey@theralase.com                                                                     

Greg Bewsh
Director of Investor Relations
416-699-LASE (5273) ext. 258

Arkady Mandel
Chief Scientific Officer
416-699-LASE (5273) ext. 260

Friday, February 15, 2013

Cancer Risk Factors


Doctors often cannot explain why one person develops cancer and another does not. But research shows that certain risk factors increase the chance that a person will develop cancer. These are the most common risk factors for cancer:
  • Growing older
  • Tobacco
  • Sunlight
  • Ionizing radiation
  • Certain chemicals and other substances
  • Some viruses and bacteria
  • Certain hormones
  • Family history of cancer
  • Alcohol
  • Poor diet, lack of physical activity, or being overweight
Many of these risk factors can be avoided. Others, such as family history, cannot be avoided. People can help protect themselves by staying away from known risk factors whenever possible.
If you think you may be at risk for cancer, you should discuss this concern with your doctor. You may want to ask about reducing your risk and about a schedule for checkups.
Over time, several factors may act together to cause normal cells to become cancerous. When thinking about your risk of getting cancer, these are some things to keep in mind:
  • Not everything causes cancer.
  • Cancer is not caused by an injury, such as a bump or bruise.
  • Cancer is not contagious. Although being infected with certain viruses or bacteria may increase the risk of some types of cancer, no one can "catch" cancer from another person.
  • Having one or more risk factors does not mean that you will get cancer. Most people who have risk factors never develop cancer.
  • Some people are more sensitive than others to the known risk factors.
The sections below have more detailed information about the most common risk factors for cancer.

Growing Older

The most important risk factor for cancer is growing older. Most cancers occur in people over the age of 65. But people of all ages, including children, can get cancer, too.

Tobacco

Tobacco use is the most preventable cause of death. Each year, more than 180,000 Americans die from cancer that is related to tobacco use.
Using tobacco products or regularly being around tobacco smoke (environmental or secondhand smoke) increases the risk of cancer.
Smokers are more likely than nonsmokers to develop cancer of the lung, larynx (voice box), mouth, esophagus, bladder, kidney, throat, stomach, pancreas, or cervix. They also are more likely to develop acute myeloid leukemia (cancer that starts in blood cells).
People who use smokeless tobacco (snuff or chewing tobacco) are at increased risk of cancer of the mouth.
Quitting is important for anyone who uses tobacco - even people who have used it for many years. The risk of cancer for people who quit is lower than the risk for people who continue to use tobacco. (But the risk of cancer is generally lowest among those who never used tobacco.)
Also, for people who have already had cancer, quitting may reduce the chance of getting another cancer.
There are many resources to help people stop using tobacco:
  • Staff at the NCI's Smoking Quitline (1-877-44U-QUIT) and at LiveHelp (http://www.cancer.gov/livehelp) can talk with you about ways to quit smoking and about groups that help smokers who want to quit. Groups may offer counseling in person or by telephone.
  • A Federal Government Web site, http://www.smokefree.gov, has an online guide to quitting smoking and a list of other resources.
  • Doctors and dentists can help their patients find local programs or trained professionals who help people stop using tobacco.
  • Doctors and dentists can suggest medicine or nicotine replacement therapy, such as a patch, gum, lozenge, nasal spray, or inhaler.

Sunlight

Ultraviolet (UV) radiation comes from the sun, sunlamps, and tanning booths. It causes early aging of the skin and skin damage that can lead to skin cancer.
Doctors encourage people of all ages to limit their time in the sun and to avoid other sources of UV radiation:
  • It is best to avoid the midday sun (from mid-morning to late afternoon) whenever possible. You also should protect yourself from UV radiation reflected by sand, water, snow, and ice. UV radiation can penetrate light clothing, windshields, and windows.
  • Wear long sleeves, long pants, a hat with a wide brim, and sunglasses with lenses that absorb UV.
  • Use sunscreen. Sunscreen may help prevent skin cancer, especially sunscreen with a sun protection factor (SPF) of at least 15. But sunscreens cannot replace avoiding the sun and wearing clothing to protect the skin.
  • Stay away from sunlamps and tanning booths. They are no safer than sunlight.
Protect yourself from the sun.
Protect yourself from the sun.

Ionizing Radiation

Ionizing radiation can cause cell damage that leads to cancer. This kind of radiation comes from rays that enter the Earth's atmosphere from outer space, radioactive fallout, radon gas, x-rays, and other sources.
Radioactive fallout can come from accidents at nuclear power plants or from the production, testing, or use of atomic weapons. People exposed to fallout may have an increased risk of cancer, especially leukemia and cancers of the thyroid, breast, lung, and stomach.
Radon is a radioactive gas that you cannot see, smell, or taste. It forms in soil and rocks. People who work in mines may be exposed to radon. In some parts of the country, radon is found in houses. People exposed to radon are at increased risk of lung cancer.
Medical procedures are a common source of radiation:
  • Doctors use radiation (low-dose x-rays) to take pictures of the inside of the body. These pictures help to diagnose broken bones and other problems.
  • Doctors use radiation therapy (high-dose radiation from large machines or from radioactive substances) to treat cancer.
The risk of cancer from low-dose x-rays is extremely small. The risk from radiation therapy is slightly higher. For both, the benefit nearly always outweighs the small risk.
You should talk with your doctor if you are concerned that you may be at risk for cancer due to radiation.
If you live in a part of the country that has radon, you may wish to test your home for high levels of the gas. The home radon test is easy to use and inexpensive. Most hardware stores sell the test kit.
You should talk with your doctor or dentist about the need for each x-ray. You should also ask about shields to protect parts of the body that are not in the picture.
Cancer patients may want to talk with their doctor about how radiation treatment could increase their risk of a second cancer later on.

Certain Chemicals and Other Substances

People who have certain jobs (such as painters, construction workers, and those in the chemical industry) have an increased risk of cancer. Many studies have shown that exposure to asbestos, benzene, benzidine, cadmium, nickel, or vinyl chloride in the workplace can cause cancer.
Follow instructions and safety tips to avoid or reduce contact with harmful substances both at work and at home. Although the risk is highest for workers with years of exposure, it makes sense to be careful at home when handling pesticides, used engine oil, paint, solvents, and other chemicals.

Some Viruses and Bacteria

Being infected with certain viruses or bacteria may increase the risk of developing cancer:
Do not have unprotected sex or share needles. You can get an HPV infection by having sex with someone who is infected. You can get hepatitis B, hepatitis C, or HIV infection from having unprotected sex or sharing needles with someone who is infected.
You may want to consider getting the vaccine that prevents hepatitis B infection. Health care workers and others who come into contact with other people's blood should ask their doctor about this vaccine.
If you think you may be at risk for HIV or hepatitis infection, ask your doctor about being tested. These infections may not cause symptoms, but blood tests can show whether the virus is present. If so, the doctor may suggest treatment. Also, the doctor can tell you how to avoid infecting other people.
If you have stomach problems, see a doctor. Infection with H. pylori can be detected and treated.

Certain Hormones

Doctors may recommend hormones (estrogen alone or estrogen along with progestin) to help control problems (such as hot flashes, vaginal dryness, and thinning bones) that may occur during menopause. However, studies show that menopausal hormone therapy can cause serious side effects. Hormones may increase the risk of breast cancer, heart attack, stroke, or blood clots.
A woman considering menopausal hormone therapy should discuss the possible risks and benefits with her doctor.
Diethylstilbestrol (DES), a form of estrogen, was given to some pregnant women in the United States between about 1940 and 1971. Women who took DES during pregnancy may have a slightly higher risk of developing breast cancer. Their daughters have an increased risk of developing a rare type of cancer of the cervix. The possible effects on their sons are under study.
Women who believe they took DES and daughters who may have been exposed to DES before birth should talk with their doctor about having checkups.

Family History of Cancer

Most cancers develop because of changes (mutations) in genes. A normal cell may become a cancer cell after a series of gene changes occur. Tobacco use, certain viruses, or other factors in a person's lifestyle or environment can cause such changes in certain types of cells.
Some gene changes that increase the risk of cancer are passed from parent to child. These changes are present at birth in all cells of the body.
It is uncommon for cancer to run in a family. However, certain types of cancer do occur more often in some families than in the rest of the population. For example, melanoma and cancers of the breast, ovary, prostate, and colon sometimes run in families. Several cases of the same cancer type in a family may be linked to inherited gene changes, which may increase the chance of developing cancers. However, environmental factors may also be involved. Most of the time, multiple cases of cancer in a family are just a matter of chance.
If you think you may have a pattern of a certain type of cancer in your family, you may want to talk to your doctor. Your doctor may suggest ways to try to reduce your risk of cancer. Your doctor also may suggest exams that can detect cancer early.
You may want to ask your doctor about genetic testing. These tests can check for certain inherited gene changes that increase the chance of developing cancer. But inheriting a gene change does not mean that you will definitely develop cancer. It means that you have an increased chance of developing the disease.

Alcohol

Having more than two drinks each day for many years may increase the chance of developing cancers of the mouth, throat, esophagus, larynx, liver, and breast. The risk increases with the amount of alcohol that a person drinks. For most of these cancers, the risk is higher for a drinker who uses tobacco.
Doctors advise people who drink to do so in moderation. Drinking in moderation means no more than one drink per day for women and no more than two drinks per day for men.

Poor Diet, Lack of Physical Activity, or Being Overweight

People who have a poor diet, do not have enough physical activity, or are overweight may be at increased risk of several types of cancer. For example, studies suggest that people whose diet is high in fat have an increased risk of cancers of the colon, uterus, and prostate. Lack of physical activity and being overweight are risk factors for cancers of the breast, colon, esophagus, kidney, and uterus.
Choose a diet rich in fruits and vegetables.
Choose a diet rich in fruits and vegetables.
Having a healthy diet, being physically active, and maintaining a healthy weight may help reduce cancer risk. Doctors suggest the following:
  • Eat well: A healthy diet includes plenty of foods that are high in fiber, vitamins, and minerals. This includes whole-grain breads and cereals and 5 to 9 servings of fruits and vegetables every day. Also, a healthy diet means limiting foods high in fat (such as butter, whole milk, fried foods, and red meat).
  • Be active and maintain a healthy weight: Physical activity can help control your weight and reduce body fat. Most scientists agree that it is a good idea for an adult to have moderate physical activity (such as brisk walking) for at least 30 minutes on 5 or more days each week.
Source: National Cancer Institute

Monday, October 22, 2012

Theralase Photo Dynamic Compounds Destroy Cancer


Toronto, Ontario – October 22, 2012, Theralase Technologies Inc. (TSX-V: TLT) announced today the successful results of preclinical studies (in-vitro and in-vivo) demonstrating significant destruction of various brain and colon cancer cell lines. The new proprietary Theralase treatment sharply delayed the tumour progression, when attacked by the Theralase patented light activated Photo Dynamic Compounds (PDCs), signifying a new and broadly promising approach to cancer treatment. When treated with the Theralase PDCs, cancerous mice survived cancer-free for more than 100 days post-treatment, a highly significant milestone.

The scientific data supporting this breakthrough was presented and well received recently at the 9th International Symposium of Photodynamic Therapy and Photodiagnosis in Clinical Practice held in Brixen, Italy. The Theralase presentation was made by Dr. Lothar Lilge, Senior Scientist, Ontario Cancer Institute / Princess Margaret Cancer Centre, University Health Network (UHN) and confirms the significance of the successful research conducted by Theralase in collaboration with UHN scientists, validating this scientific work on the international stage.

Dr. Lothar Lilge stated that, "These preclinical results demonstrate that the Theralase Photo Dynamic Compounds appear to be highly effective (100% cancer cell kill) when used to destroy various cancer cell lines in-vitro; specifically, brain glioma (U-87 and F-98) and in-vivo; specifically, colon cancer (CT-26WT), in the treatment of subcutaneous cancer tumours in Balb/c mice. Mice enrolled in the study, presented with subcutaneous cancerous lesions of approximately 6 mm in size prior to treatment, which is standard for these preclinical models. The statistically significant improvement in survival times make these results even more encouraging, as a number of mice are still alive today living cancer free, 100 days post treatment. Moreover, we believe that tested PDCs may have potential for Type I (oxygen independent) PDT effect; hence, their clinical use would represent a significant gain in cancer therapy.”

Dr. Arkady Mandel, Chief Scientific Officer at Theralase Inc. stated that, "We were delighted with the extremely promising results of our latest cancer studies, which demonstrate significant anticancer destruction of Theralase’s PDCs in all tested in-vitro studies and  in difficult to treat in-vivo cancer models, without significant optimization. With optimization, the ability of the Theralase PDCs to target and destroy cancerous tumours could be even more enhanced. There are a number of obvious advantages for the use of Theralase’s PDCs in the destruction of cancer that have been established by this body of work, such as: the Photo Dynamic Therapy (PDT) effect has been achieved at lower concentrations compared to aminolevulinic acid, also known as ALA (ALA is a currently approved FDA PDC) and with lower dark toxicity (PDC alone with no light) compared to methylene blue (another PDC), the Theralase PDCs have potential for Type I (oxygen independent) PDT effect and lastly were able to induce tumour necrosis (cell death) in mice that allowed prolonged survival, cancer free, in excess of 100 days of observation. New evidence from experimental and clinical studies increasingly points to a lack of oxygen content or hypoxia in solid tumours to be strongly associated with tumour propagation, malignant progression and resistance to therapy and it has thus become one of the central issues in tumour physiology and cancer treatment. Therefore, with the latest scientific data in hand, Theralase’s PDT has the potential to become more expeditiously integrated into the mainstream of cancer treatment.”

Roger Dumoulin-White, President and CEO of Theralase stated, “This new research extends the opportunity of Theralase’s patented PDC technology to have a successful impact on two additional devastating forms of cancer; specifically, brain and colon cancer. Our research has demonstrated a kill rate of effectively 100% in specific human brain and colon cancer cells lines. With the high mouse survival rate, which is approximately equivalent to 11 years “cancer free” in humans, being observed in this study, these results lay the groundwork for further preclinical work for these specific cancers. If the preclinical work is proven successful, this would lead to human clinical trials as early as 2013. Theralase plans to aggressively pursue commercialization of its ground-breaking PDT technology through the FDA regulatory approval process and is on track to commence FDA Phase 1 human clinical trials as early as this time next year. Theralase plans to continue its research and development at an accelerated pace to optimize and expand its growing patent portfolio of PDCs that are able to destroy a variety of life threatening cancers.”

About Theralase Technologies Inc.:
Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing. Theralase is currently developing patented Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary and patented laser technology.

 For further information please visit www.theralase.com , regulatory filings may be viewed by visiting www.sedar.com.
 
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information
Roger Dumoulin-White                                                                                   
President & CEO,                       
416-447-8455 ext. 225                                          
rwhite@theralase.com

Kristina Hachey
Chief Financial Officer
416-447-8455 ext. 224
khachey@theralase.com 

Arkady Mandel
Chief Scientific Officer
416-447-8455 ext. 242
amandel@theralase.com

Greg Bewsh
Director of Investor Relations,
416-447-8455 ext. 262
gbewsh@theralase.com